{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:14:50Z","timestamp":1783487690380,"version":"3.55.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82303137"],"award-info":[{"award-number":["82303137"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82573064, 82073030"],"award-info":[{"award-number":["82573064, 82073030"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation of China","doi-asserted-by":"crossref","award":["2025JJ60499"],"award-info":[{"award-number":["2025JJ60499"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation of China","doi-asserted-by":"crossref","award":["2022JJ20083"],"award-info":[{"award-number":["2022JJ20083"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-026-02934-9","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:23:52Z","timestamp":1778858632000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["EBV (LMP1) enhances cisplatin resistance by enhancing degradation of interferon regulatory factor 3"],"prefix":"10.1186","volume":"24","author":[{"given":"Yueshuo","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangjian","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"2934_CR1","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/d41586-024-00653-0","volume":"627","author":"L Young","year":"2024","unstructured":"Young L. Epstein-Barr virus at 60. Nature. 2024;627:492\u20134. https:\/\/doi.org\/10.1038\/d41586-024-00653-0.","journal-title":"Nature"},{"key":"2934_CR2","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1016\/j.cell.2022.08.026","volume":"185","author":"B Damania","year":"2022","unstructured":"Damania B, Kenney SC. Raab-Traub, N. Epstein-Barr virus: Biology and clinical disease. Cell. 2022;185:3652\u201370. https:\/\/doi.org\/10.1016\/j.cell.2022.08.026.","journal-title":"Cell"},{"key":"2934_CR3","doi-asserted-by":"publisher","unstructured":"Yu-Pei C, et al. Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. J Clin Oncol. 2021;39. https:\/\/doi.org\/10.1200\/jco.20.03237.","DOI":"10.1200\/jco.20.03237"},{"key":"2934_CR4","doi-asserted-by":"publisher","unstructured":"Yuan Z, et al. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. N Engl J Med. 2019;381. https:\/\/doi.org\/10.1056\/NEJMoa1905287.","DOI":"10.1056\/NEJMoa1905287"},{"key":"2934_CR5","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1200\/jco.20.03237","volume":"39","author":"Y Chen","year":"2021","unstructured":"Chen Y, et al. Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. J Clin oncology: official J Am Soc Clin Oncol. 2021;39:840\u201359. https:\/\/doi.org\/10.1200\/jco.20.03237.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"key":"2934_CR6","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.annonc.2020.12.007","volume":"32","author":"P Bossi","year":"2021","unstructured":"Bossi P, et al. Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals oncology: official J Eur Soc Med Oncol. 2021;32:452\u201365. https:\/\/doi.org\/10.1016\/j.annonc.2020.12.007.","journal-title":"Annals oncology: official J Eur Soc Med Oncol"},{"key":"2934_CR7","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/s0140-6736(19)30956-0","volume":"394","author":"Y-P Chen","year":"2019","unstructured":"Chen Y-P, et al. Nasopharyngeal carcinoma. Lancet. 2019;394:64\u201380. https:\/\/doi.org\/10.1016\/s0140-6736(19)30956-0.","journal-title":"Lancet"},{"key":"2934_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41392-020-00376-4","volume":"6","author":"Y Cao","year":"2021","unstructured":"Cao Y, et al. Targeting the signaling in Epstein-Barr virus-associated diseases: mechanism, regulation, and clinical study. Signal Transduct Target Ther. 2021;6:15. https:\/\/doi.org\/10.1038\/s41392-020-00376-4.","journal-title":"Signal Transduct Target Ther"},{"key":"2934_CR9","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41467-021-21043-4","volume":"12","author":"Y Liu","year":"2021","unstructured":"Liu Y, et al. Tumour heterogeneity and intercellular networks of nasopharyngeal carcinoma at single cell resolution. Nat Commun. 2021;12:741. https:\/\/doi.org\/10.1038\/s41467-021-21043-4.","journal-title":"Nat Commun"},{"key":"2934_CR10","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1038\/emi.2015.20","volume":"4","author":"Y Shen","year":"2015","unstructured":"Shen Y, Zhang S, Sun R, Wu T, Qian J. Understanding the interplay between host immunity and Epstein-Barr virus in NPC patients. Emerg Microbes Infect. 2015;4:e20. https:\/\/doi.org\/10.1038\/emi.2015.20.","journal-title":"Emerg Microbes Infect"},{"key":"2934_CR11","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1360\/SSV-2024-0184","volume":"54","author":"Y CAO","year":"2024","unstructured":"CAO Y, ZHANG Z. Research progress on EBV infection and metabolic remodeling. SCIENTIA SINICA Vitae. 2024;54:2288\u201397. https:\/\/doi.org\/10.1360\/SSV-2024-0184.","journal-title":"SCIENTIA SINICA Vitae"},{"key":"2934_CR12","doi-asserted-by":"publisher","unstructured":"Liang Wei W, Sizun J, Benjamin E. Epstein-Barr Virus LMP1-Mediated Oncogenicity. J Virol. 2017;91. https:\/\/doi.org\/10.1128\/jvi.01718-16.","DOI":"10.1128\/jvi.01718-16"},{"key":"2934_CR13","doi-asserted-by":"publisher","first-page":"513383","DOI":"10.3389\/fimmu.2020.513383","volume":"11","author":"P Wang","year":"2020","unstructured":"Wang P, et al. Epstein-Barr Virus Early Protein BFRF1 Suppresses IFN-beta Activity by Inhibiting the Activation of IRF3. Front Immunol. 2020;11:513383. https:\/\/doi.org\/10.3389\/fimmu.2020.513383.","journal-title":"Front Immunol"},{"key":"2934_CR14","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.4049\/jimmunol.1501605","volume":"198","author":"MJG Hooykaas","year":"2017","unstructured":"Hooykaas MJG, et al. EBV MicroRNA BART16 Suppresses Type I IFN Signaling. J Immunol. 2017;198:4062\u201373. https:\/\/doi.org\/10.4049\/jimmunol.1501605.","journal-title":"J Immunol"},{"key":"2934_CR15","doi-asserted-by":"publisher","unstructured":"Liu XQ, Sadaoka T, Krogmann T, Cohen JI. Epstein-Barr Virus (EBV) Tegument Protein BGLF2 Suppresses Type I Interferon Signaling To Promote EBV Reactivation. Journal of Virology. 2020;94. https:\/\/doi.org\/10.1128\/JVI.00258-20.","DOI":"10.1128\/JVI.00258-20"},{"key":"2934_CR16","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1080\/15548627.2020.1758416","volume":"17","author":"G Vilmen","year":"2021","unstructured":"Vilmen G, et al. BHRF1, a BCL2 viral homolog, disturbs mitochondrial dynamics and stimulates mitophagy to dampen type I IFN induction. Autophagy. 2021;17:1296\u2013315. https:\/\/doi.org\/10.1080\/15548627.2020.1758416.","journal-title":"Autophagy"},{"key":"2934_CR17","doi-asserted-by":"publisher","first-page":"115026","DOI":"10.1016\/j.bcp.2022.115026","volume":"200","author":"M Al Hamrashdi","year":"2022","unstructured":"Al Hamrashdi M, Brady G. Regulation of IRF3 activation in human antiviral signaling pathways. Biochem Pharmacol. 2022;200:115026. https:\/\/doi.org\/10.1016\/j.bcp.2022.115026.","journal-title":"Biochem Pharmacol"},{"key":"2934_CR18","doi-asserted-by":"publisher","unstructured":"L W, et al. LMP1 signaling pathway activates IRF4 in latent EBV infection and a positive circuit between PI3K and Src is required. Oncogene. 2016;36. https:\/\/doi.org\/10.1038\/onc.2016.380.","DOI":"10.1038\/onc.2016.380"},{"key":"2934_CR19","doi-asserted-by":"publisher","unstructured":"Shunbin N, Alex D, Bryant C, Gretchen GD L, B., Joseph S. TRAF6 and the three C-terminal lysine sites on IRF7 are required for its ubiquitination-mediated activation by the tumor necrosis factor receptor family member latent membrane protein 1. Mol Cell Biol. 2008;28. https:\/\/doi.org\/10.1128\/mcb.00785-08.","DOI":"10.1128\/mcb.00785-08"},{"key":"2934_CR20","doi-asserted-by":"publisher","unstructured":"Shunbin N, Joseph S. The A20 deubiquitinase activity negatively regulates LMP1 activation of IRF7. J Virol. 2010;84. https:\/\/doi.org\/10.1128\/jvi.00364-10.","DOI":"10.1128\/jvi.00364-10"},{"key":"2934_CR21","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/s41467-017-00101-w","volume":"8","author":"J Xing","year":"2017","unstructured":"Xing J, et al. TRIM29 promotes DNA virus infections by inhibiting innate immune response. Nat Commun. 2017;8:945. https:\/\/doi.org\/10.1038\/s41467-017-00101-w.","journal-title":"Nat Commun"},{"key":"2934_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41421-018-0031-4","volume":"4","author":"Q Li","year":"2018","unstructured":"Li Q, et al. Author Correction to: TRIM29 negatively controls antiviral immune response through targeting STING for degradation. Cell discovery. 2018;4:25. https:\/\/doi.org\/10.1038\/s41421-018-0031-4. Erratum.","journal-title":"Cell discovery"},{"key":"2934_CR23","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/s41467-017-00101-w","volume":"8","author":"J Xing","year":"2017","unstructured":"Xing J, et al. TRIM29 promotes DNA virus infections by inhibiting innate immune response. Nat Commun. 2017;8:945. https:\/\/doi.org\/10.1038\/s41467-017-00101-w.","journal-title":"Nat Commun"},{"key":"2934_CR24","doi-asserted-by":"publisher","first-page":"e1011186","DOI":"10.1371\/journal.ppat.1011186","volume":"19","author":"WY Lui","year":"2023","unstructured":"Lui WY, et al. Suppression of cGAS- and RIG-I-mediated innate immune signaling by Epstein-Barr virus deubiquitinase BPLF1. PLoS Pathog. 2023;19:e1011186. https:\/\/doi.org\/10.1371\/journal.ppat.1011186.","journal-title":"PLoS Pathog"},{"key":"2934_CR25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41698-021-00153-8","volume":"5","author":"Y Li","year":"2021","unstructured":"Li Y, et al. Stabilization of p18 by deubiquitylase CYLD is pivotal for cell cycle progression and viral replication. NPJ Precis Oncol. 2021;5:14. https:\/\/doi.org\/10.1038\/s41698-021-00153-8.","journal-title":"NPJ Precis Oncol"},{"key":"2934_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41419-017-0081-9","volume":"9","author":"X Liu","year":"2018","unstructured":"Liu X, et al. Epstein-Barr virus encoded latent membrane protein 1 suppresses necroptosis through targeting RIPK1\/3 ubiquitination. Cell Death Dis. 2018;9:53. https:\/\/doi.org\/10.1038\/s41419-017-0081-9.","journal-title":"Cell Death Dis"},{"key":"2934_CR27","doi-asserted-by":"publisher","unstructured":"K F H, Alan KS. Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death. Int J Cancer. 2009;126. https:\/\/doi.org\/10.1002\/ijc.24945.","DOI":"10.1002\/ijc.24945"},{"key":"2934_CR28","doi-asserted-by":"publisher","unstructured":"Shi F et al. Epstein-Barr virus-driven metabolic alterations contribute to the viral lytic reactivation and tumor progression in nasopharyngeal carcinoma. J Med Virol. 2024;96. https:\/\/doi.org\/10.1002\/jmv.29634.","DOI":"10.1002\/jmv.29634"},{"key":"2934_CR29","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41419-024-06419-w","volume":"15","author":"Y Li","year":"2024","unstructured":"Li Y, et al. CYLD induces high oxidative stress and DNA damage through class I HDACs to promote radiosensitivity in nasopharyngeal carcinoma. Cell Death Dis. 2024;15:95. https:\/\/doi.org\/10.1038\/s41419-024-06419-w.","journal-title":"Cell Death Dis"},{"key":"2934_CR30","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41698-021-00153-8","volume":"5","author":"Y Li","year":"2021","unstructured":"Li Y, et al. Stabilization of p18 by deubiquitylase CYLD is pivotal for cell cycle progression and viral replication. NPJ precision Oncol. 2021;5:14. https:\/\/doi.org\/10.1038\/s41698-021-00153-8.","journal-title":"NPJ precision Oncol"},{"key":"2934_CR31","doi-asserted-by":"publisher","first-page":"ra20","DOI":"10.1126\/scisignal.2002521","volume":"5","author":"Y Tanaka","year":"2012","unstructured":"Tanaka Y, Chen ZJ. STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway. Sci Signal. 2012;5:ra20. https:\/\/doi.org\/10.1126\/scisignal.2002521.","journal-title":"Sci Signal"},{"key":"2934_CR32","doi-asserted-by":"publisher","unstructured":"Louise D, Hans Henrik G, Rune H. Viral recognition and the antiviral interferon response. EMBO J. 2023;42. https:\/\/doi.org\/10.15252\/embj.2022112907.","DOI":"10.15252\/embj.2022112907"},{"key":"2934_CR33","doi-asserted-by":"publisher","unstructured":"Yang P, et al. TRIM21-mediated ubiquitination of SQSTM1\/p62 abolishes its Ser403 phosphorylation and enhances palmitic acid cytotoxicity. Autophagy. 2024;1\u201313. https:\/\/doi.org\/10.1080\/15548627.2024.2394308.","DOI":"10.1080\/15548627.2024.2394308"},{"key":"2934_CR34","doi-asserted-by":"publisher","first-page":"11921","DOI":"10.7150\/thno.46006","volume":"10","author":"J Hu","year":"2020","unstructured":"Hu J, et al. Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy. Theranostics. 2020;10:11921\u201337. https:\/\/doi.org\/10.7150\/thno.46006.","journal-title":"Theranostics"},{"key":"2934_CR35","doi-asserted-by":"publisher","unstructured":"Lu X et al. UBE2M-mediated neddylation of TRIM21 regulates obesity-induced inflammation and metabolic disorders. Cell Metab. 2023;35:1390\u20131405 e1398. https:\/\/doi.org\/10.1016\/j.cmet.2023.05.011.","DOI":"10.1016\/j.cmet.2023.05.011"},{"key":"2934_CR36","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/ng.3006","volume":"46","author":"DC Lin","year":"2014","unstructured":"Lin DC, et al. The genomic landscape of nasopharyngeal carcinoma. Nat Genet. 2014;46:866\u201371. https:\/\/doi.org\/10.1038\/ng.3006.","journal-title":"Nat Genet"},{"key":"2934_CR37","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1073\/pnas.0611128104","volume":"104","author":"M Rowe","year":"2007","unstructured":"Rowe M, et al. Host shutoff during productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion. Proc Natl Acad Sci U S A. 2007;104:3366\u201371. https:\/\/doi.org\/10.1073\/pnas.0611128104.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2934_CR38","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.canlet.2016.05.032","volume":"380","author":"J Lu","year":"2016","unstructured":"Lu J, et al. EBV-LMP1 suppresses the DNA damage response through DNA-PK\/AMPK signaling to promote radioresistance in nasopharyngeal carcinoma. Cancer Lett. 2016;380:191\u2013200. https:\/\/doi.org\/10.1016\/j.canlet.2016.05.032.","journal-title":"Cancer Lett"},{"key":"2934_CR39","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41392-020-0151-9","volume":"5","author":"L Xie","year":"2020","unstructured":"Xie L, et al. Drp1-dependent remodeling of mitochondrial morphology triggered by EBV-LMP1 increases cisplatin resistance. Signal Transduct Target Ther. 2020;5:56. https:\/\/doi.org\/10.1038\/s41392-020-0151-9.","journal-title":"Signal Transduct Target Ther"},{"key":"2934_CR40","doi-asserted-by":"publisher","first-page":"e14072","DOI":"10.15252\/emmm.202114072","volume":"13","author":"L Zhao","year":"2021","unstructured":"Zhao L, et al. Conformational change of adenine nucleotide translocase-1 mediates cisplatin resistance induced by EBV-LMP1. EMBO Mol Med. 2021;13:e14072. https:\/\/doi.org\/10.15252\/emmm.202114072.","journal-title":"EMBO Mol Med"},{"key":"2934_CR41","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1084\/jem.20180139","volume":"215","author":"T Li","year":"2018","unstructured":"Li T, Chen ZJ. The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer. J Exp Med. 2018;215:1287\u201399. https:\/\/doi.org\/10.1084\/jem.20180139.","journal-title":"J Exp Med"},{"key":"2934_CR42","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/s41591-023-02369-6","volume":"29","author":"J Lv","year":"2023","unstructured":"Lv J, et al. The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment. Nat Med. 2023;29:1424\u201336. https:\/\/doi.org\/10.1038\/s41591-023-02369-6.","journal-title":"Nat Med"},{"key":"2934_CR43","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.tcb.2021.01.010","volume":"31","author":"M Bury","year":"2021","unstructured":"Bury M, Le Calv\u00e9 B, Ferbeyre G, Blank V, Lessard F. New Insights into CDK Regulators: Novel Opportunities for Cancer Therapy. Trends Cell Biol. 2021;31:331\u201344. https:\/\/doi.org\/10.1016\/j.tcb.2021.01.010.","journal-title":"Trends Cell Biol"},{"key":"2934_CR44","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/imr.13272","volume":"321","author":"P Holicek","year":"2024","unstructured":"Holicek P, et al. Type I interferon and cancer. Immunol Rev. 2024;321:115\u201327. https:\/\/doi.org\/10.1111\/imr.13272.","journal-title":"Immunol Rev"},{"key":"2934_CR45","doi-asserted-by":"publisher","unstructured":"DeKroon RM, Gunawardena HP, Edwards R, Raab-Traub N. Global Proteomic Changes Induced by the Epstein-Barr Virus Oncoproteins Latent Membrane Protein 1 and 2A. mBio. 2018;9. https:\/\/doi.org\/10.1128\/mBio.00959-18.","DOI":"10.1128\/mBio.00959-18"},{"key":"2934_CR46","doi-asserted-by":"publisher","unstructured":"Wang L, Ning S. New Look of EBV LMP1 Signaling Landscape. Cancers (Basel). 2021;13. https:\/\/doi.org\/10.3390\/cancers13215451.","DOI":"10.3390\/cancers13215451"},{"key":"2934_CR47","doi-asserted-by":"publisher","first-page":"e1004890","DOI":"10.1371\/journal.ppat.1004890","volume":"11","author":"H Greenfeld","year":"2015","unstructured":"Greenfeld H, et al. TRAF1 Coordinates Polyubiquitin Signaling to Enhance Epstein-Barr Virus LMP1-Mediated Growth and Survival Pathway Activation. PLoS Pathog. 2015;11:e1004890. https:\/\/doi.org\/10.1371\/journal.ppat.1004890.","journal-title":"PLoS Pathog"},{"key":"2934_CR48","doi-asserted-by":"publisher","unstructured":"Wang L, et al. The Ubiquitin Sensor and Adaptor Protein p62 Mediates Signal Transduction of a Viral Oncogenic Pathway. mBio. 2021;12(e0109721). https:\/\/doi.org\/10.1128\/mBio.01097-21.","DOI":"10.1128\/mBio.01097-21"},{"key":"2934_CR49","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41419-017-0081-9","volume":"9","author":"X Liu","year":"2018","unstructured":"Liu X, et al. Epstein-Barr virus encoded latent membrane protein 1 suppresses necroptosis through targeting RIPK1\/3 ubiquitination. Cell Death Dis. 2018;9:53. https:\/\/doi.org\/10.1038\/s41419-017-0081-9.","journal-title":"Cell Death Dis"},{"key":"2934_CR50","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.4161\/cc.20771","volume":"11","author":"L Li","year":"2012","unstructured":"Li L, et al. Viral oncoprotein LMP1 disrupts p53-induced cell cycle arrest and apoptosis through modulating K63-linked ubiquitination of p53. Cell Cycle. 2012;11:2327\u201336. https:\/\/doi.org\/10.4161\/cc.20771.","journal-title":"Cell Cycle"},{"key":"2934_CR51","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.virol.2013.10.018","volume":"448","author":"GL Bentz","year":"2014","unstructured":"Bentz GL, et al. KSHV LANA and EBV LMP1 induce the expression of UCH-L1 following viral transformation. Virology. 2014;448:293\u2013302. https:\/\/doi.org\/10.1016\/j.virol.2013.10.018.","journal-title":"Virology"},{"key":"2934_CR52","doi-asserted-by":"publisher","unstructured":"Hulse M, Johnson SM, Boyle S, Caruso LB, Tempera I. Epstein-Barr Virus-Encoded Latent Membrane Protein 1 and B-Cell Growth Transformation Induce Lipogenesis through Fatty Acid Synthase. J Virol. 2021;95. https:\/\/doi.org\/10.1128\/JVI.01857-20.","DOI":"10.1128\/JVI.01857-20"},{"key":"2934_CR53","doi-asserted-by":"publisher","first-page":"10144","DOI":"10.1128\/JVI.05035-11","volume":"85","author":"GL Bentz","year":"2011","unstructured":"Bentz GL, Whitehurst CB, Pagano JS. Epstein-Barr virus latent membrane protein 1 (LMP1) C-terminal-activating region 3 contributes to LMP1-mediated cellular migration via its interaction with Ubc9. J Virol. 2011;85:10144\u201353. https:\/\/doi.org\/10.1128\/JVI.05035-11.","journal-title":"J Virol"},{"key":"2934_CR54","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/s41467-023-36523-y","volume":"14","author":"JY Li","year":"2023","unstructured":"Li JY, et al. TRIM21 inhibits irradiation-induced mitochondrial DNA release and impairs antitumour immunity in nasopharyngeal carcinoma tumour models. Nat Commun. 2023;14:865. https:\/\/doi.org\/10.1038\/s41467-023-36523-y.","journal-title":"Nat Commun"},{"key":"2934_CR55","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1080\/15548627.2020.1761653","volume":"17","author":"Y Wu","year":"2021","unstructured":"Wu Y, et al. Selective autophagy controls the stability of transcription factor IRF3 to balance type I interferon production and immune suppression. Autophagy. 2021;17:1379\u201392. https:\/\/doi.org\/10.1080\/15548627.2020.1761653.","journal-title":"Autophagy"},{"key":"2934_CR56","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.4049\/jimmunol.181.3.1780","volume":"181","author":"R Higgs","year":"2008","unstructured":"Higgs R, et al. The E3 ubiquitin ligase Ro52 negatively regulates IFN-production post-pathogen recognition by polyubiquitin-mediated degradation of IRF3. J Immunol. 2008;181:1780\u20136. https:\/\/doi.org\/10.4049\/jimmunol.181.3.1780.","journal-title":"J Immunol"},{"key":"2934_CR57","doi-asserted-by":"publisher","unstructured":"Manocha GD et al. Regulatory role of TRIM21 in the type-I interferon pathway in Japanese encephalitis virus-infected human microglial cells. J Neuroinflamm. 2014;11. https:\/\/doi.org\/10.1186\/1742-2094-11-24.","DOI":"10.1186\/1742-2094-11-24"},{"key":"2934_CR58","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.3389\/fimmu.2018.02479","volume":"9","author":"H Liu","year":"2018","unstructured":"Liu H, Li M, Song Y, Xu W. TRIM21 Restricts Coxsackievirus B3 Replication, Cardiac and Pancreatic Injury via Interacting With MAVS and Positively Regulating IRF3-Mediated Type-I Interferon Production. Front Immunol. 2018;9:2479. https:\/\/doi.org\/10.3389\/fimmu.2018.02479.","journal-title":"Front Immunol"},{"key":"2934_CR59","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.4049\/jimmunol.0803126","volume":"182","author":"K Yang","year":"2009","unstructured":"Yang K, et al. TRIM21 is essential to sustain IFN regulatory factor 3 activation during antiviral response. J Immunol. 2009;182:3782\u201392. https:\/\/doi.org\/10.4049\/jimmunol.0803126.","journal-title":"J Immunol"},{"key":"2934_CR60","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41392-024-02095-6","volume":"10","author":"B Li","year":"2025","unstructured":"Li B, et al. Redox regulation: mechanisms, biology and therapeutic targets in diseases. Signal Transduct Target Ther. 2025;10:72. https:\/\/doi.org\/10.1038\/s41392-024-02095-6.","journal-title":"Signal Transduct Target Ther"},{"key":"2934_CR61","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1089\/ars.2023.0252","volume":"41","author":"C Chahla","year":"2024","unstructured":"Chahla C, Kovacic H, Ferhat L, Leloup L. Pathological Impact of Redox Post-Translational Modifications. Antioxid Redox Signal. 2024;41:152\u201380. https:\/\/doi.org\/10.1089\/ars.2023.0252.","journal-title":"Antioxid Redox Signal"},{"key":"2934_CR62","doi-asserted-by":"publisher","unstructured":"Yan S, et al. IRF3 reduces adipose thermogenesis via ISG15-mediated reprogramming of glycolysis. J Clin Invest. 2021;131. https:\/\/doi.org\/10.1172\/JCI144888.","DOI":"10.1172\/JCI144888"},{"key":"2934_CR63","doi-asserted-by":"publisher","first-page":"5762","DOI":"10.1038\/s41467-020-19627-7","volume":"11","author":"M Tian","year":"2020","unstructured":"Tian M, et al. IRF3 prevents colorectal tumorigenesis via inhibiting the nuclear translocation of beta-catenin. Nat Commun. 2020;11:5762. https:\/\/doi.org\/10.1038\/s41467-020-19627-7.","journal-title":"Nat Commun"},{"key":"2934_CR64","doi-asserted-by":"publisher","first-page":"e1002496","DOI":"10.1371\/journal.ppat.1002496","volume":"8","author":"KS Lee","year":"2012","unstructured":"Lee KS, et al. Viral cyclins mediate separate phases of infection by integrating functions of distinct mammalian cyclins. PLoS Pathog. 2012;8:e1002496. https:\/\/doi.org\/10.1371\/journal.ppat.1002496.","journal-title":"PLoS Pathog"},{"key":"2934_CR65","doi-asserted-by":"publisher","first-page":"10821","DOI":"10.1128\/JVI.00891-15","volume":"89","author":"LM Williams","year":"2015","unstructured":"Williams LM, Niemeyer BF, Franklin DS, Clambey ET, van Dyk LF. A Conserved Gammaherpesvirus Cyclin Specifically Bypasses Host p18(INK4c) To Promote Reactivation from Latency. J Virol. 2015;89:10821\u201331. https:\/\/doi.org\/10.1128\/JVI.00891-15.","journal-title":"J Virol"},{"key":"2934_CR66","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.ygyno.2011.04.034","volume":"122","author":"G He","year":"2011","unstructured":"He G, Kuang J, Khokhar A, Siddik Z. The impact of S- and G2-checkpoint response on the fidelity of G1-arrest by cisplatin and its comparison to a non-cross-resistant platinum(IV) analog. Gynecol Oncol. 2011;122:402\u20139. https:\/\/doi.org\/10.1016\/j.ygyno.2011.04.034.","journal-title":"Gynecol Oncol"},{"key":"2934_CR67","doi-asserted-by":"publisher","first-page":"e59848","DOI":"10.1371\/journal.pone.0059848","volume":"8","author":"H Shen","year":"2013","unstructured":"Shen H, Perez R, Davaadelger B, Maki C. Two 4\u00a0N cell-cycle arrests contribute to cisplatin-resistance. PLoS ONE. 2013;8:e59848. https:\/\/doi.org\/10.1371\/journal.pone.0059848.","journal-title":"PLoS ONE"},{"key":"2934_CR68","doi-asserted-by":"publisher","first-page":"23383","DOI":"10.18632\/oncotarget.8110","volume":"7","author":"K Luong","year":"2016","unstructured":"Luong K, Wang L, Roberts B, Wahl J, Peng A. Cell fate determination in cisplatin resistance and chemosensitization. Oncotarget. 2016;7:23383\u201394. https:\/\/doi.org\/10.18632\/oncotarget.8110.","journal-title":"Oncotarget"},{"key":"2934_CR69","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1091\/mbc.E19-09-0515","volume":"31","author":"A Granada","year":"2020","unstructured":"Granada A, et al. The effects of proliferation status and cell cycle phase on the responses of single cells to chemotherapy. Mol Biol Cell. 2020;31:845\u201357. https:\/\/doi.org\/10.1091\/mbc.E19-09-0515.","journal-title":"Mol Biol Cell"},{"key":"2934_CR70","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nri3845","volume":"15","author":"L Zitvogel","year":"2015","unstructured":"Zitvogel L, Galluzzi L, Kepp O, Smyth M, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol. 2015;15:405\u201314. https:\/\/doi.org\/10.1038\/nri3845.","journal-title":"Nat Rev Immunol"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-026-02934-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02934-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02934-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:29:36Z","timestamp":1783484976000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-026-02934-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2934"],"URL":"https:\/\/doi.org\/10.1186\/s12964-026-02934-9","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"8 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"395"}}